pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$BOLDBoundless Bio, Inc.

$BOLD
San Diego, CA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
BBI-940
Human Epidermal Growth Factor Receptor 2 Negative Breast…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancerterminatedn=8
  • phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplificationsactive not recruitingn=85
  • phase1Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplificationsterminatedn=19
🐶 Hiring Signal
No open roles indexed yet — view Boundless Bio, Inc. jobs →

News

  • Novartis projects slowed growth, pins hopes on billions in pipeline potential
    With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.
    biospace · 3h ago
  • Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
    The go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
    biospace · 4h ago
  • Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in Congress
    Sen. Bernie Sanders pushed back on assumptions that Trump would veto an expanded Medicare plan. “I am not absolutely certain that Trump would not sign it,” he said.
    stat · 6h ago
  • Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event
    Panelists at Fierce Biotech's London Life Sciences Week event discussed whether Europe can pull its weight in biopharma investment next year against the gravitational pull of the U.S. and China.
    fiercebiotech · 2d ago
  • Opinion: Medical school should start after students take the Step 1 exam
    “It’s time for a radical reimagining of medical education,” write Rachel Fabi and Amy Caruso Brown.
    stat · 3d ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 3d ago
  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 6d ago
  • Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
    Policy uncertainty is hampering the growth of U.S. biotech as China rises thanks to carefully planned investment in the industry, experts said during a BioSpace webinar.
    biospace · 8d ago
  • STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
    Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug.
    stat · 9d ago
  • STAT+: Bill Ackman’s bold plan to transform brain research
    Billionaire Bill Ackman as a bold plan to transform brain research, spurred by a tragic backstory.
    stat · 10d ago
view all news mentions →
identifiers
ticker
$BOLD
SEC CIK
0001782303
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 35m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?